Commentary|Articles|October 27, 2023

SCOPE Europe 2023 Panel: From Concept to Reality—The eSource-to-EDC Revolution Gathers Pace

Interactive panel discussed the evolving area of data transfer and the usage of EHR-to-EDC.

In an interactive panel at SCOPE Europe 2023 in Barcelona, Spain, participants discussed the concept of eSource data captured in EHRs transforming the way clinical trials are being run. A video of the discussion can be found below.

Moderated by Mats Sundgren, PhD, senior industry scientific director, i-HD (European Institute for Innovation through Health Data), the panel members included Peter Casteleyn, director, clinical data collection solutions-EHR, The Janssen Pharmaceutical Companies of Johnson and Johnson, Paul Jacobs, associate director, development innovation, Regeneron Pharmaceuticals, and Joe Lengfellner, senior director, clinical research informatics, Memorial Sloan Kettering Cancer Center.

The first question posed to the panel from Sundgren was around the challenges and opportunities each are facing in the area of data transfer. The participants highlighted data collection and quality as challenges. Specifically, the amount of data and the increasing workload it is creating for operational staff. However, there are opportunities to streamline these processes with new and improved technology.

The panel also focused on value-generation, which tied the conversation back to the earlier point on increasing workload. Organizations are trying to pinpoint the cost of queries and patient/site monitoring and how much time they are spending on them. What is the breakeven point for expending resources on these new technologies in order to achieve improved data transfer?

To conclude, the panel spoke on what the future could look like in this space. The panelists were in agreement that interoperability and adoption are trends stakeholders should be keeping top of mind in the next few years.


Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
Recruitment in the Age of AI: Q&A with John Worden, Javara
In this Q&A, John Worden, chief commercial officer at Javara, discusses why clinical trial recruitment has remained stubbornly one-size-fits-all, how AI can identify patients at scale without displacing the clinician relationships that drive trust, and what care-integrated research engagement needs to look like for health systems, sponsors, and sites.